PDF herunterladen
CC BY 4.0 · TH Open 2020; 04(04): e322-e331
DOI: 10.1055/s-0040-1718885
Original Article

Common and Rare Variants in Genes Associated with von Willebrand Factor Level Variation: No Accumulation of Rare Variants in Swedish von Willebrand Disease Patients

Eric Manderstedt
1   Department of Environmental Science and Bioscience, Kristianstad University, Kristianstad, Sweden
,
Christina Lind-Halldén
1   Department of Environmental Science and Bioscience, Kristianstad University, Kristianstad, Sweden
,
Stefan Lethagen
2   Department for Coagulation Disorders, University Hospital, Malmö, Sweden
3   National Hemophilia Center, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark
4   Sobi, Stockholm, Sweden
,
Christer Halldén
1   Department of Environmental Science and Bioscience, Kristianstad University, Kristianstad, Sweden
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Genome-wide association studies (GWASs) have identified genes that affect plasma von Willebrand factor (VWF) levels. ABO showed a strong effect, whereas smaller effects were seen for VWF, STXBP5, STAB2, SCARA5, STX2, TC2N, and CLEC4M. This study screened comprehensively for both common and rare variants in these eight genes by resequencing their coding sequences in 104 Swedish von Willebrand disease (VWD) patients. The common variants previously associated with the VWF level were all accumulated in the VWD patients compared to three control populations. The strongest effect was detected for blood group O coded for by the ABO gene (71 vs. 38% of genotypes). The other seven VWF level associated alleles were enriched in the VWD population compared to control populations, but the differences were small and not significant. The sequencing detected a total of 146 variants in the eight genes. Excluding 70 variants in VWF, 76 variants remained. Of the 76 variants, 54 had allele frequencies > 0.5% and have therefore been investigated for their association with the VWF level in previous GWAS. The remaining 22 variants with frequencies < 0.5% are less likely to have been evaluated previously. PolyPhen2 classified 3 out of the 22 variants as probably or possibly damaging (two in STAB2 and one in STX2); the others were either synonymous or benign. No accumulation of low frequency (0.05–0.5%) or rare variants (<0.05%) in the VWD population compared to the gnomAD (Genome Aggregation Database) population was detected. Thus, rare variants in these genes do not contribute to the low VWF levels observed in VWD patients.

Keywords

von Willebrand factor - von Willebrand disease - rare variant - DNA sequencing

Supplementary Material



Publikationsverlauf

Eingereicht: 18. Juni 2020

Angenommen: 15. September 2020

Artikel online veröffentlicht:
31. Oktober 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).

Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood 2013; 122 (23) 3735-3740
    CrossrefPubMedGoogle Scholar
  • 2 Swystun LL, James PD. Genetic diagnosis in hemophilia and von Willebrand disease. Blood Rev 2017; 31 (01) 47-56
    CrossrefPubMedGoogle Scholar
  • 3 Smith NL, Chen MH, Dehghan A. et al. Wellcome Trust Case Control Consortium. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121 (12) 1382-1392
    CrossrefPubMedGoogle Scholar
  • 4 Huffman JE, de Vries PS, Morrison AC. et al. Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF. Blood 2015; 126 (11) e19-e29
    CrossrefPubMedGoogle Scholar
  • 5 Sabater-Lleal M, Huffman JE, de Vries PS. et al. INVENT Consortium, MEGASTROKE Consortium of the International Stroke Genetics Consortium (ISGC). Genome-wide association transethnic meta-analyses identifies novel associations regulating coagulation factor VIII and von Willebrand factor plasma levels. Circulation 2019; 139 (05) 620-635
    CrossrefPubMedGoogle Scholar
  • 6 Johnsen JM, Auer PL, Morrison AC. et al. NHLBI Exome Sequencing Project. Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project. Blood 2013; 122 (04) 590-597
    CrossrefPubMedGoogle Scholar
  • 7 Lanke E, Johansson AM, Halldén C, Lethagen S. Genetic analysis of 31 Swedish type 1 von Willebrand disease families reveals incomplete linkage to the von Willebrand factor gene and a high frequency of a certain disease haplotype. J Thromb Haemost 2005; 3 (12) 2656-2663
    CrossrefPubMedGoogle Scholar
  • 8 Manderstedt E, Lind-Halldén C, Lethagen S, Halldén C. Genetic variation in the von Willebrand factor gene in Swedish von Willebrand disease patients. TH Open 2018; 2 (01) e39-e48
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 9 Johansson AM, Halldén C, Säll T, Lethagen S. Variation in the VWF gene in Swedish patients with type 1 von Willebrand disease. Ann Hum Genet 2011; 75 (04) 447-455
    CrossrefPubMedGoogle Scholar
  • 10 Halldén C, Nilsson D, Säll T, Lind-Halldén C, Lidén AC, Ljung R. Origin of Swedish hemophilia A mutations. J Thromb Haemost 2012; 10 (12) 2503-2511
    CrossrefPubMedGoogle Scholar
  • 11 van Loon J, Dehghan A, Weihong T. et al. Genome-wide association studies identify genetic loci for low von Willebrand factor levels. Eur J Hum Genet 2016; 24 (07) 1035-1040
    CrossrefPubMedGoogle Scholar
  • 12 Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24 (03) 123-134
    CrossrefPubMedGoogle Scholar
  • 13 Manderstedt E, Lind-Halldén C, Lethagen S, Halldén C. Genetic variation in the C-type lectin receptor CLEC4M in type 1 von Willebrand disease patients. PLoS One 2018; 13 (02) e0192024
    CrossrefPubMedGoogle Scholar
  • 14 Lind-Halldén C, Manderstedt E, Carlberg D, Lethagen S, Halldén C. Genetic variation in the syntaxin-binding protein STXBP5 in type 1 von Willebrand disease patients. Thromb Haemost 2018; 118 (08) 1382-1389
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Sanders YV, van der Bom JG, Isaacs A. et al. WiN Study Group. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease. J Thromb Haemost 2015; 13 (06) 956-966
    CrossrefPubMedGoogle Scholar
  • 16 Swystun LL, Lai JD, Notley C. et al. The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. J Clin Invest 2018; 128 (09) 4057-4073
    CrossrefPubMedGoogle Scholar
  • 17 Mufti AH, Ogiwara K, Swystun LL. et al. European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups. The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance. Blood Adv 2018; 2 (13) 1585-1594
    CrossrefPubMedGoogle Scholar
  • 18 Castaman G, Tosetto A, Eikenboom JC, Rodeghiero F. Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza. J Thromb Haemost 2010; 8 (09) 2078-2080
    CrossrefPubMedGoogle Scholar